On December 11, 2025, Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop, and deliver potentially curative therapies that address the underlying causes of heart disease, announced the pricing of its underwritten public offering of 50,000,000 total units for gross proceeds of $60 million prior to deducting underwriting discounts and commissions and offering expenses. Wilson Sonsini Goodrich & Rosati advised Tenaya on the transaction.

The offering is comprised of 50,000,000 units at a public offering price of $1.20 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $1.50 per share. The offering is expected to close on or about December 15, 2025, subject to satisfaction of customary closing conditions.

The Wilson Sonsini team that advised Tenaya on the transaction includes Jennifer Knapp, Emily Coskey, Tamara Labanowski, Alison Sechrest, and Alex Stebbins.

For more information, please see Tenaya’s press release.